Impact of sex on the efficacy of first-line Y90-Radioembolization plus/minus Sorafenib versus Sorafenib alone in Patients With BCLC B/C HCC – An exploratory, retrospective analysis of the Phase III SORAMIC/SARAH/SIRVENIB trials

Impact of sex on the efficacy of first-line Y90-Radioembolization plus/minus Sorafenib versus Sorafenib alone in Patients With BCLC B/C HCC – An exploratory, retrospective analysis of the Phase III SORAMIC/SARAH/SIRVENIB trials - LMU-RAD01231

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034675

Enrollment

1243

Registered

2024-08-22

Start date

2024-08-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22

Interventions

Group 1: The data of the study population from the Phase II/III studies SORAMIC, SARAH and SIRVENIB form the basis for the retrospective analysis. Patients with intermediate or advanced stage hepatoce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated within the SORAMIC, SARAH and SIRVENIB study

Exclusion criteria

Exclusion criteria: Missing information regarding gender

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) based on existing patient data from treatment to death. treatment until death.	—

Secondary

Measure	Time frame
- Progression-Free Survival (PFS) - Liver-specific progression-free survival (hepatic Progression-Free Survival, hPFS) - Tolerability/toxicity	—

Countries

Germany

Contacts

Public ContactMax Seidensticker

Klinik und Poliklinik für Radiologie; LMU Klinikum

Max.Seidensticker@med.uni-muenchen.de+49 89 4400 73620

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026